Search our Database of Scientific Publications and Authors

I’m looking for a

    3376 results match your criteria Prolactinoma

    1 OF 68

    Natural and molecular history of prolactinoma: insights from amouse model.
    Oncotarget 2018 Jan 27;9(5):6144-6155. Epub 2017 Dec 27.
    Unité INSERM 1185, Faculté de Médecine Paris Sud, Université Paris-Saclay, le Kremlin-Bicêtre, France.
    Lactotroph adenoma, also called prolactinoma, is the most common pituitary tumor but little is known about its pathogenesis. Mouse models of prolactinoma can be useful to better understand molecular mechanisms involved in abnormal lactotroph cell proliferation and secretion. We have previously developed a prolactin receptor deficient () mouse, which develops prolactinoma. Read More

    Clinicopathological significance of baseline T2-weighted signal intensity in functional pituitary adenomas.
    Pituitary 2018 Feb 19. Epub 2018 Feb 19.
    Division of Endocrinology and Metabolism, Capa, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, 34090, Istanbul, Turkey.
    Purpose: To assess baseline T2-weighted signal intensity (T2-WSI) of functional pituitary adenomas (FPA), and to investigate the relationship of baseline T2-WSI with clinical features, histopathological granulation patterns, and response to treatment in patients with acromegaly, prolactinoma and Cushing's disease (CD).

    Methods: Somatotroph adenomas (n = 87), prolactinomas (n = 78) and corticotroph adenomas (n = 29) were included in the study. Baseline T2-WSI findings (grouped as hypo-, iso- and hyperintense) were compared with hormone levels, tumor diameter, granulation patterns and response to treatment. Read More

    Clinical Features and Response to Treatment of Prolactinomas in Children and Adolescents: A Retrospective Single-Centre Analysis and Review of the Literature.
    Horm Res Paediatr 2018 Feb 16. Epub 2018 Feb 16.
    Division of Paediatric Endocrinology and Diabetes, Department of Paediatrics, University Hospital Heidelberg, Heidelberg, Germany.
    Background: Paediatric prolactinomas are rare. The aim of this study was to investigate the clinical features and outcome of paediatric patients with prolactinomas.

    Methods: In this single-centre retrospective analysis, clinical, biochemical, and radiological features of all paediatric patients with pituitary adenomas diagnosed between 2000 and 2016 were evaluated. Read More

    Transnasal transphenoidal elevation of optic chiasm in secondary empty sella syndrome following prolactinoma treatment.
    World Neurosurg 2018 Feb 5. Epub 2018 Feb 5.
    Department of Neurosurgery, Duke University Hospitals.
    Background: Prolactinomas are typically treated non-surgically with a dopamine agonist. However, once the tumor shrinks, adjacent eloquent structures such as the optic apparatus can become skeletonized and herniate into the dilated parasellar space.

    Case Description: We describe here a 48-year-old man with a prolactin-secreting macroadenoma treated with cabergoline who presented with progressive bitemporal hemianopsia. Read More

    The prolactin-release inhibitor paeoniflorin suppresses proliferation and induces apoptosis in prolactinoma cells via the mitochondria-dependent pathway.
    J Cell Biochem 2018 Feb 1. Epub 2018 Feb 1.
    Endocrinology and Metabolism Group, Sydney Institute of Health Sciences/Sydney Institute of Traditional Chinese Medicine, NSW 2000 Australia.
    Prolactinomas are the most prevalent functional pituitary adenomas that cause chronic pathological hyperprolactinemia. Prolactin is known to promote cell growth and inhibit apoptosis in cells. Paeoniflorin is the principal component of radix Paeoniae alba (the main ingredient in some traditional herbal formulas clinically used for hyperprolactinemia-associated disorders). Read More

    Treatment of aggressive prolactinoma with temozolomide: A case report and review of literature up to date.
    Medicine (Baltimore) 2017 Nov;96(47):e8733
    Department of Neurosurgery, West China Hospital of Sichuan University, Chengdu, Sichuan Province.
    Rationale: Aggressive pituitary adenomas and pituitary carcinomas are rare and demand multiple treatment strategies. Temozolomide, an orally active alkylating chemotherapeutic agent, has recently been recommended as a salvage medication for refractory pituitary adenomas or carcinomas.

    Patient Concerns: A 17-year-old male presenting with aggressive prolactinoma that continued to progress despite surgery, gamma knife, and dopamine agonists. Read More

    Ectopic Prolactinoma Presenting as Bacterial Meningitis: A Diagnostic Conundrum.
    World Neurosurg 2018 Jan 26. Epub 2018 Jan 26.
    Introduction: Prolactinomas may rarely present with meningitis and cerebrospinal fluid (CSF) rhinorrhea secondary to erosion of the wall of the sella turcica. It is even more un-common for this abnormal communication to be caused by an ectopic prolactinoma arising from the sphenoid sinus and eroding into the sella. This atypical growth pattern makes diagnosis very difficult, as there may be no displacement of the normal pituitary gland. Read More

    Multiple Eyelid Cysts (Apocrine and Eccrine Hidrocystomas, Trichilemmal Cyst, and Hybrid Cyst) in a Patient With a Prolactinoma.
    Ophthal Plast Reconstr Surg 2018 Jan 18. Epub 2018 Jan 18.
    David G. Cogan Laboratory of Ophthalmic Pathology, Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, U.S.A.
    A 53-year-old man presented with smooth-domed, variegated cysts (polycystic disease) of all 4 eyelids, worse on the left side. Some of the cysts were clear, while others were creamy-white colored. In addition, multiple, very fine vesicopapules were noted along the eyelid margins. Read More

    Characteristics of pericytes in diethylstilbestrol (DES)-induced pituitary prolactinoma in rats.
    Med Mol Morphol 2018 Jan 17. Epub 2018 Jan 17.
    Division of Histology and Cell Biology, Department of Anatomy, Jichi Medical University, School of Medicine, 3311-1 Yakushiji, Shimotsuke, Tochigi, 329-0498, Japan.
    Prolactinomas are the most common tumor of the human pituitary. They result in excessive prolactin secretion and important changes in the vasculature. Pericytes are perivascular cells associated with capillaries and have crucial roles in physiological and pathological neovascularization. Read More

    Up- and Down-regulated Leukemia-related Protein 16 Affects ERα Expression and Prolactin Secretion by GH3 Cells.
    Biomed Environ Sci 2017 Dec;30(12):938-942
    Chinese PLA General Hospital, Beijing 100853, China.
    Prolactinoma is an estrogen-related tumor and leukemia-related protein 16 (LRP16) is correlated with the progression of estrogen-related tumors, but the regulatory mechanism between LRP16 and prolactinoma remain unclear. This study demonstrates a variation in LRP16 with estrogen receptor α (ERα) in prolactinoma models and the up and downregulation effects of LRP16 on prolactin secretion of pituitary adenomas cells (GH3 cells). In our study, 50 male SD rats (30-day-old) were randomly divided into five groups of 10 rats each. Read More

    Broad clinical spectrum and diverse outcomes of prolactinoma with pediatric onset: medication-resistant and recurrent cases.
    Endocr J 2017 Dec 27. Epub 2017 Dec 27.
    Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Korea.
    Prolactinoma is a benign tumor of the pituitary gland that rarely occurs in children and adolescents; thus, the clinical spectrum and long-term prognosis in these patients remain unknown. This study was performed to investigate the long-term outcomes of medical treatment and the prognostic factors for remission and relapse in children and adolescents with prolactinoma. Three male subjects and four female subjects between the ages of 7- and 17-years-old were included in this study. Read More

    Cabergoline Tapering Is Almost Always Successful in Patients With Macroprolactinomas.
    J Endocr Soc 2017 Mar 16;1(3):221-230. Epub 2017 Feb 16.
    Service d'Endocrinologie et des Maladies de la Reproduction and Centre de Référence des Maladies Endocriniennes Rares de la Croissance, and.
    Context: Cabergoline (CAB) is very effective in the treatment of macroprolactinomas, but there are few data on the CAB dose necessary to achieve and maintain normal prolactin (PRL) levels.

    Design And Patients: We retrospectively studied 260 patients. CAB was introduced at a mean dose of 0. Read More

    Case Report of a Prolactinoma in a Patient With a NovelMutation and Bilateral Pheochromocytomas.
    J Endocr Soc 2017 Nov 23;1(11):1401-1407. Epub 2017 Oct 23.
    Neuroendocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114.
    Pheochromocytomas are neuroendocrine tumors that can arise sporadically or be inherited as a familial disease, and they may occur in isolation or as part of a multitumor syndrome. Familial disease typically presents in younger patients with a higher risk of multifocality. Recently, the tumor suppressor MYC-associated factor X () gene has been implicated as a cause of familial isolated pheochromocytoma and paraganglioma. Read More

    Nonfunctional pancreatic endocrine tumor in the peripancreatic region in a Chinese patient with multiple endocrine neoplasia type 1.
    J Int Med Res 2018 Feb 14;46(2):908-915. Epub 2017 Sep 14.
    1 Department of Endocrinology, Tianjin Medical University General Hospital, Heping District, Tianjin, China.
    Nonfunctional pancreatic neuroendocrine tumors (NF-pNETs) in patients with multiple endocrine neoplasia type 1 (MEN1), which results from a mutation in the MEN1 gene, are commonly small, multiple tumors located in the pancreatic head and inside the pancreatic parenchyma. We herein describe a 35-year-old woman with bone pain and a 7-year history of a prolactinoma. She was clinically diagnosed with MEN1 based on the presence of the prolactinoma and parathyroid hyperplasia. Read More

    P21and p27are correlated with the development and invasion of prolactinoma.
    J Neurooncol 2018 Feb 11;136(3):485-494. Epub 2017 Dec 11.
    Key Laboratory of Central Nervous System Injury Research, Beijing Neurosurgical Institute, Capital Medical University, Tiantanxili 6#, Beijing, 100050, China.
    Cell cycle control can prevent excessive proliferative response in the pituitary homeostasis. Cyclin dependent kinases (Cdks) are modulated by cyclins or Cdk inhibitors, such as p21 and p27, which can regulate cell cycle progression from the G1 to S phases. This study was conducted to evaluate the levels and the promoter region methylation status of p21 and p27 in prolactinomas (PRL) and analyze their association with clinicopathologic features. Read More

    Prolactinoma through the female life cycle.
    Endocrine 2018 Jan 24;59(1):16-29. Epub 2017 Nov 24.
    Multidisciplinary Pituitary and Skull Base Tumor Center, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 419, New York, NY, 10065, USA.
    Prolactinomas are the most common secretory pituitary adenoma. They typically occur in women in the 3rd-6th decade of life and rarely in the pediatric population or after menopause. Most women present with irregular menses and/or infertility. Read More

    Repair of Cerebrospinal Fluid Leakage Using a Transfrontal, Radial Adipofascial Flap: An Individual Approach Supported by Three-Dimensional Printing for Surgical Planning.
    World Neurosurg 2018 Feb 23;110:315-318. Epub 2017 Nov 23.
    Department of Orofaciallary Surgery, University Hospital of Cologne, Cologne, Germany.
    Background: Leakage of cerebrospinal fluid (CSF) because of large prolactinomas represents a complex issue. Because of limited anatomic space, multiple leakage sites, and scarce locally available tissue for repair, surgical possibilities are limited. We report an initial case of using a radial fasciocutaneous flap applied subfrontally to cover a large skull base defect, supported by preoperative three-dimensional (3D) printing for surgical planning. Read More

    Pediatric prolactinoma: initial presentation, treatment, and long-term prognosis.
    Eur J Pediatr 2018 Jan 22;177(1):125-132. Epub 2017 Nov 22.
    Department of Pediatrics and Pediatric Hematology/Oncology, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Rahel-Straus-Strasse 10, 26133, Oldenburg, Germany.
    Prolactinoma is a rare pituitary adenoma secreting prolactin. Studies on diagnostics, treatment, and prognosis in pediatric prolactinoma patients are rare. We analyzed clinical presentation, response to treatment, and prognosis of 27 pediatric prolactinoma patients (10 m/17 f. Read More

    [Valvular heart disease in relation to the treatment of hyperprolactinemia with dopamine agonists].
    Vnitr Lek Fall 2017;63(9):561-565
    Adverse effect of dopamine agonists on the heart valves aroused much attention some time ago. Gradually, as data accumulated, the approach to the problem was rationalised and further examinations were only recommended in indicated cases. The paper reviews the current knowledge about the treatment of hyperprolactinemia with dopamine agonists and the risk of valvular disease. Read More

    Pituitary atypical teratoid rhabdoid tumor in a patient with prolactinoma: A unique description.
    Neuropathology 2017 Nov 6. Epub 2017 Nov 6.
    Unit of Neurosurgery, Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy.
    Atypical teratoid rhabdoid tumor (ATRT) is an aggressive tumor of the CNS and characteristically occurs in the pediatric age. In adulthood, ATRT is rare and it is mainly localized in the cerebral hemispheres. Only 16 cases of ATRT have been described in the sellar region up to now. Read More

    A novel "total pituitary hormone index" as an indicator of postoperative pituitary function in patients undergoing resection of pituitary adenomas.
    Oncotarget 2017 Oct 7;8(45):79111-79125. Epub 2017 Mar 7.
    Department of Neurosurgery, Fuzhou General Hospital, Fujian Medical University, Fuzhou, P. R. China.
    The purpose of this study was to investigate the differences between pre- and postoperative pituitary hormone levels in patients undergoing surgical resection of pituitary adenoma and to identify factors associated with preoperative hypopituitarism. Data from 81 patients with histologically confirmed functioning and non-functioning pituitary adenomas (NFPA) who underwent transsphenoidal resection from January 2011 to December 2013 were retrospectively analyzed. Logistic regression was applied to analyze factors associated with preoperative hypopituitarism. Read More

    Relation among Aromatase P450 and Tumoral Growth in Human Prolactinomas.
    Int J Mol Sci 2017 Nov 1;18(11). Epub 2017 Nov 1.
    Laboratory of Neuroendocrinology, INCyL and IBSAL, University of Salamanca, 37007 Salamanca, Spain.
    The pituitary gland is part of hypothalamic-pituitary-gonadal axis, which controls development, reproduction, and aging in humans and animals. In addition, the pituitary gland is regulated mainly by hormones and neurotransmitters released from the hypothalamus and by systemic hormones secreted by target glands. Aromatase P450, the enzyme responsible for the catabolization of aromatizable androgens to estrogens, is expressed in different parts of body, including the pituitary gland. Read More

    Pituitary Adenoma Associated With Rathke's Cleft Cyst: Report of 15 Cases.
    Can J Neurol Sci 2018 Jan 6;45(1):68-75. Epub 2017 Nov 6.
    1Department of Neurosurgery, Beijing Tiantan Hospital,Capital Medical University,Beijing,China.
    Objective: The concomitant presence of pituitary adenoma (PA) with Rathke's cleft cyst (RCC) is rare, and most of the literature published is case reports. RCC's clinicopathological features have not been well described.

    Methods: We retrospectively reviewed the data of 15 patients with PA associated with RCC. Read More

    Cabergoline-induced fibrosis of prolactinomas: a neurosurgical perspective.
    BMJ Case Rep 2017 Nov 3;2017. Epub 2017 Nov 3.
    Division of Neurosurgery, National University Hospital (NUH), Singapore.
    Presently, the standard of care for prolactinomas, a type of pituitary adenoma, is dopaminergic agents such as bromocriptine and cabergoline. However, dopaminergic agents may induce fibrosis of cardiac valves leading to valvular insufficiency, necessitating surgical treatment of prolactinoma. Fibrosis of prolactinoma can be induced by prolonged medical treatment with bromocriptine, and this usually occurs after years of treatment. Read More

    mutations in Brazilian patients with sporadic pituitary adenomas: a single-center evaluation.
    Endocr Connect 2017 Nov 26;6(8):914-925. Epub 2017 Oct 26.
    Department of Internal Medicine and Endocrine UnitMedical School and Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil
    Aryl hydrocarbon receptor-interacting protein () gene mutations () are the most frequent germline mutations found in apparently sporadic pituitary adenomas (SPA). Our aim was to evaluate the frequency ofamong young Brazilian patients with SPA. We performed an observational cohort study between 2013 and 2016 in a single referral center. Read More

    Sex differences in the pituitary TGFβ1 system: The role of TGFβ1 in prolactinoma development.
    Front Neuroendocrinol 2017 Oct 24. Epub 2017 Oct 24.
    Instituto de Biología y Medicina Experimental, Consejo Nacional de Investigaciones Científicas y Técnicas, V. Obligado 2490, 1428 Buenos Aires, Argentina. Electronic address:
    Prolactinomas are the most frequent functioning pituitary adenomas, and sex differences in tumor size, behavior and incidence have been described. These differences have been associated with earlier diagnosis in woman, as well as with serum estradiol levels. Experimental models of prolactinomas in rodents also show a higher incidence in females, and recent findings suggest that gender differences in the transforming growth factor beta 1 (TGFβ1) system might be involved in the sex-specific development of prolactinomas in these models. Read More

    Novel Germline p.Gly42ValMutation in a Family with Multiple Endocrine Neoplasia Type 1 - Excellent Response of Prolactinoma to Cabergoline.
    Ann Clin Lab Sci 2017 Sep;47(5):606-610
    Endocrinology, William Harvey Research Institute, Bart's and the London School of Medicine, Queen Mary University of London, London, UK
    We report on a 27-year-old male patient presenting with renal colic secondary to hyperparathyroidism. Further investigations confirmed a diagnosis of type 1 multiple endocrine neoplasia and revealed a 2.0 cm pancreatic neuroendocrine tumour as well as a pituitary macroadenoma with significantly elevated prolactin levels. Read More

    Males with prolactinoma are at increased risk of incident cardiovascular disease.
    Clin Endocrinol (Oxf) 2018 Jan 8;88(1):71-76. Epub 2017 Nov 8.
    Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
    Objective: To investigate whether the risk of incident cardiovascular disease (CVD) is increased in patients with prolactinoma.

    Design: Population-based, retrospective, open-cohort study using The Health Improvement Network (THIN) database.

    Patients: A total of 2233 patients with prolactinoma and 10 355 matched controls (1:5 ratio) from UK General Practices contributing to THIN were included. Read More

    Optimal timing of dopamine agonist withdrawal in patients with hyperprolactinemia: a systematic review and meta-analysis.
    Endocrine 2018 Jan 17;59(1):50-61. Epub 2017 Oct 17.
    Department of Neurosurgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 200025, Shanghai, China.
    Purpose: Dopamine agonists (DAs) are recommended as first-line treatment for patients with hyperprolactinemia. Generally, it is accepted that patients with hyperprolactinemia do not need lifelong medication, but the optimal timing for DA withdrawal has not been determined. The aim of this systematic review and meta-analysis is to assess the impact of DA withdrawal on the clinical outcomes of patients with hyperprolactinemia, and to explore possible factors affecting successful DA withdrawal. Read More

    Analysis of MEN1 c.482G>A (p.Gly161Asp) mutation in a pedigree with familial multiple endocrine neoplasia type 1.
    Mol Med Rep 2017 Dec 10;16(6):8973-8976. Epub 2017 Oct 10.
    Department of Endocrinology and Metabolism, Genetic and Prenatal Diagnosis Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China.
    Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant disorder characterized by the development of neuroendocrine tumors, which in turn are caused by mutations in the MEN1 gene. In the present study, a case of a 46‑year‑old woman who was clinically diagnosed with MEN1 based on the presence of prolactinoma and bilateral parathyroid adenoma was reported. The patient's serum prolactin (PRL) levels were successfully controlled via bromocriptine therapy, and the serum levels of calcium and intact parathyroid hormone (PTH) reduced one day following parathyroidectomy. Read More

    Improvement in cognitive abilities following cabergoline treatment in patients with a prolactin-secreting pituitary adenoma.
    Int Clin Psychopharmacol 2018 Mar;33(2):98-102
    Departments of Mental Health, CIBERSAM.
    Hyperprolactinaemia may affect sexual and reproductive functioning. However, recent studies suggest that increased prolactin levels may also have negative effects on cognition. We aimed to study whether the reduction in prolactin levels by cabergoline in patients with hyperprolactinaemia is followed by an improvement in cognitive tasks. Read More

    α-Glucosidase inhibitory and cytotoxic botryorhodines from mangrove endophytic fungus Trichoderma sp. 307.
    Nat Prod Res 2017 Oct 12:1-6. Epub 2017 Oct 12.
    a School of Marine Sciences , Sun Yat-Sen University , Guangzhou , China.
    One new depsidone, botryorhodine H (1), together with three known analogues, botryorhodines C, D and G (2-4), were obtained from the mangrove endophytic fungus Trichoderma sp. 307 by co-culturing with Acinetobacter johnsonii B2. Structures were determined by 1D and 2D NMR analyses and high-resolution mass spectrum. Read More

    Diagnosis and treatment of TSH-secreting adenomas: review of a longtime experience in a reference center.
    J Endocrinol Invest 2017 Oct 11. Epub 2017 Oct 11.
    Neuroendocrine Unit, Division of Endocrinology and Metabolism, Escola Paulista de Medicina, Universidade Federal de São Paulo, Rua Botucatu, 806, Vila Clementino, São Paulo, CEP 04023-062, Brazil.
    Purpose: TSH-secreting pituitary adenomas are among the less prevalent pituitary tumors, corresponding to 0.9-1.5% of all pituitary adenomas in surgical series. Read More

    SUBCLINICAL IMPAIRMENT OF LEFT VENTRICULAR LONGITUDINAL FUNCTION IN PATIENTS WITH PROLACTINOMAS.
    Endocr Pract 2017 12 11;23(12):1379-1386. Epub 2017 Oct 11.
    Objective: Hyperprolactinemia has been associated with endothelial dysfunction and a wide range of cardiovascular risk factors, thus it can potentially lead to cardiac dysfunction. The present study was designed to interrogate our hypothesis that hyperprolactinemia can contribute to preclinical impaired left ventricular function.

    Methods: Thirty-one prolactinoma patients and 60 healthy volunteers were prospectively recruited. Read More

    Pituitary Tumor Suppression by Combination of Cabergoline and Chloroquine.
    J Clin Endocrinol Metab 2017 Oct;102(10):3692-3703
    Department of Neurosurgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
    Context: The dopamine agonist cabergoline (CAB) has been used widely in the treatment of prolactinomas and other types of pituitary adenomas, but its clinical use is hampered by intolerance in some patients with prolactinoma and lack of effectiveness in other pituitary tumor types. Chloroquine (CQ) is an old drug widely used to treat malaria. Recent studies, including our own, have revealed that CAB and CQ are involved in induction of autophagy and activation of autophagic cell death. Read More

    Beneficial Effects of High Doses of Cabergoline in the Treatment of Giant Prolactinoma Resistant to Dopamine Agonists: A Case Report with a 21-Year Follow-Up.
    Horm Res Paediatr 2018 26;89(1):63-70. Epub 2017 Sep 26.
    Endocrinology Service, Brasília University Hospital, Brasília, Brazil.
    Introduction: Prolactinomas are pituitary tumors with a very low prevalence in childhood and adolescence compared to adulthood. This condition is preferentially treated with dopamine agonists. Resistance to these drugs is rare. Read More

    Resolution of dopamine agonist-resistant hyperprolactinemia by hysterectomy: a case report.
    Gynecol Endocrinol 2018 Mar 19;34(3):199-201. Epub 2017 Sep 19.
    a Department of Obstetrics and Gynecology , Hyogo Prefectural Amagasaki General Medical Center , Amagasaki , Japan.
    Prolactin-producing uterine leiomyomas are very rare. Although hyperprolactinemia rapidly improves after removal of such leiomyomas, no preoperative diagnostic test has been established for prolactin-producing uterine leiomyomas. A 45-year-old Japanese woman, gravida 3 para 3, was referred to our hospital for further examination of hyperprolactinemia resistant to a dopamine agonist. Read More

    Notch system is differentially expressed and activated in pituitary adenomas of distinct histotype, tumor cell lines and normal pituitaries.
    Oncotarget 2017 Aug 6;8(34):57072-57088. Epub 2017 Jul 6.
    Centro de Investigaciones y Transferencia del Noroeste de la Provincia de Buenos Aires, CITNOBA (UNNOBA-CONICET), Universidad Nacional del Noroeste de la Provincia de Buenos Aires, Pergamino, 2700 Buenos Aires, Argentina.
    Pituitary adenomas are among the most frequent intracranial neoplasms and treatment depends on tumor subtype and clinical features. Unfortunately, non responder cases occur, then new molecular targets are needed. Notch system component expression and activation data are scarce in pituitary tumorigenesis, we therefore aimed to characterize Notch system in pituitary tumors of different histotype. Read More

    [Prolactin-secreting microadenoma in menopausal women].
    Pan Afr Med J 2017 5;27:177. Epub 2017 Jul 5.
    Service d'Endocrinologie, CHU Farhat Hached de Sousse, Tunisie.
    Prolactin-secreting adenoma is rare in elderly women. Patient's clinical picture may be confused with that of menopause, making diagnosis sometimes difficult. We report the case of a 57-year old woman with a 2-year history of secondary amenorrhea without hot flushes associated with galactorrhea in order to highlight the peculiarities of prolactin-secreting microadenomas. Read More

    Cerebrospinal Fluid Leak Rhinorrhea after Systemic Erlotinib Chemotherapy for Metastatic Lung Cancer: A Familiar Problem from an Unfamiliar Culprit.
    World Neurosurg 2017 Dec 5;108:992.e11-992.e14. Epub 2017 Sep 5.
    Department of Neurological Surgery, Wexner Medical Center, The Ohio State University, College of Medicine, Columbus, Ohio, USA; Department of Otolaryngology-Head and Neck Surgery, Wexner Medical Center, The Ohio State University, College of Medicine, Columbus, Ohio, USA. Electronic address:
    Background: Cerebrospinal fluid (CSF) rhinorrhea after medical therapy for pituitary prolactinoma is a rare but well-described phenomenon. To our knowledge, no CSF leaks have been reported after targeted medical treatment of pituitary or anterior skull base metastases. We report this unusual case to raise awareness of spontaneous CSF leaks in the setting of skull base metastatic disease. Read More

    Lesson to be remembered from a skull base tumor.
    Neurochirurgie 2017 Sep 4;63(4):334-335. Epub 2017 Sep 4.
    Institut Mitovasc, unité CNRS 6214/Inserm1083, université d'Angers, 49100 Angers, France; Service d'endocrinologie diabétologie nutrition, centre de référence des maladies rares de la réceptivité hormonale, CHU d'Angers, Angers, France. Electronic address:
    The natural history of giant prolactinomas is not known. While it is commonly accepted that the enlargement of microadenoma is rare and more limited than macroadenoma, it is so far uncommon that macroadenoma progress to giant adenoma. Thus, spontaneous enlargement of adenomas is poorly documented. Read More

    1 OF 68